Can we treat systemic lupus erythematosus and other autoimmune diseases without oral steroids?

Merayo, Eugenia Enríquez; Sciascia, Savino; Roccatello, Dario; Cuadrado, María J.

doi:10.1080/1744666x.2018.1527219

Cited by 7 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Special information will be needed on long-term surveillance, and rheumatologists should be open-minded to have better therapeutic options in the future. 65,66 The question if we are prepared to abandon the oral GCs has an emphatic answer: no, we are not ready. A recent monocentric, 12-month, superiority, open-label, randomized controlled trial compared the efficacy in preventing flares of 2 regimens: maintenance versus withdrawal of 5 mg/d prednisone in patients with clinically quiescent SLE.…”

Section: Corticosteroids: Are We Ready To Abandon Oral Corticosteroids?mentioning

confidence: 99%

See 1 more Smart Citation

Controversies in Systemic Lupus Erythematosus

et al. 2021

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is characterized by great clinical heterogeneity. The objectives of its management are to make a timely diagnosis and to initiate treatment as promptly as possible so organ damage can be avoided while at the same time exposure to potentially toxic drugs is minimized so that its overall course and outcome improve. In reviewing the current literature, it became quite clear that there are specific topics in which controversies do exist. These include how to treat patients with incomplete lupus erythematosus, the real possibility of abandoning altogether the use of oral glucocorticoids, and the pros and cons of the use of cyclophosphamide and mycophenolate mofetil for the induction treatment of lupus nephritis. Herein we discuss different points of view regarding these still unresolved issues; these comments represent a debate that took place during the PANLARVirtual Congress (Pan American League of Associations for Rheumatology) and that was organized by the PANLAR Lupus study group, GLADEL (Grupo Latino Americano De Estudio del Lupus) on September 19, 2020.

show abstract

Section: Corticosteroids: Are We Ready To Abandon Oral Corticosteroids?mentioning

confidence: 99%

“…An education program should emphasize both efficacy and safety issues. Special information will be needed on long-term surveillance, and rheumatologists should be open-minded to have better therapeutic options in the future 65,66 …”

Section: Corticosteroids: Are We Ready To Abandon Oral Corticosteroids?mentioning

confidence: 99%